CHMP Supports Cosentyx’s Approval in Europe to Treat nr-axSpA
The Committee for Medicinal Products for Human Use (CHMP) is recommending the approval of Cosentyx (secukinumab) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Recommendations from CHMP, part of the European Medicines Agency, are typically accepted by the European…